W H Sharfman
Overview
Explore the profile of W H Sharfman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stein J, Soni A, Danilova L, Cottrell T, Gajewski T, Hodi F, et al.
Ann Oncol
. 2019 Jan;
30(4):589-596.
PMID: 30689736
Background: With increasing anti-PD-1 therapy use in patients with melanoma and other tumor types, there is interest in developing early on-treatment biomarkers that correlate with long-term patient outcome. An understanding...
2.
Longo D, Duffey P, Kopp W, Heyes M, Alvord W, Sharfman W, et al.
Clin Immunol
. 1999 Mar;
90(2):173-81.
PMID: 10080828
We determined whether a classical conditioning paradigm may be used to condition immunologic responses in normal human subjects receiving an optimal immunostimulating dose of recombinant human interferon-gamma (rhIFN-gamma). We conducted...
3.
Gause B, Sharfman W, Janik J, Curti B, Steis R, Urba W, et al.
Cancer Invest
. 1998 Jul;
16(6):374-80.
PMID: 9679527
The purpose of this trial was to determine the toxicity and antineoplastic activity of cisplatin, carboplatin, tamoxifen, and interferon-alpha (IFN-alpha) in patients with advanced melanoma. Eleven patients with metastatic melanoma...
4.
Fenton R, Steis R, Madara K, Zea A, Ochoa A, Janik J, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Sep;
19(5):364-74.
PMID: 8941876
We performed a prospective, randomized study to determine whether subcutaneous administration of interleukin-2 (IL-2) in combination with an autologous renal cell vaccine is feasible and can potentiate antitumor immunity. Seventeen...
5.
Curti B, Ochoa A, Urba W, Alvord W, Kopp W, Powers G, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Jul;
19(4):296-308.
PMID: 8877723
The adoptive transfer of anti-CD3-stimulated T killer (T-AK) cells was tested with different bolus and infusional interleukin-2 (IL-2) regimens, and anti-CD3 stimulation procedures to determine immunologic and antitumor effects in...
6.
Curti B, Urba W, Longo D, Janik J, Sharfman W, Miller L, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Mar;
19(2):142-8.
PMID: 8732697
Previous primate and rodent studies suggested that interleukin-1 alpha (IL-1 alpha) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples...
7.
Janik J, Miller L, Longo D, Powers G, Urba W, Kopp W, et al.
J Natl Cancer Inst
. 1996 Jan;
88(1):44-9.
PMID: 8847725
Background: The rising incidence of malignant melanoma and the lack of curative therapies for metastatic disease represent a therapeutic challenge. New agents effective in treating this disease are needed. Purpose:...
8.
Janik J, Sznol M, Urba W, Figlin R, Bukowski R, Fyfe G, et al.
Cancer
. 1993 Nov;
72(9):2656-9.
PMID: 8402486
Background: Interleukin-2 (IL-2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no...
9.
Smith 2nd J, Longo D, Alvord W, Janik J, Sharfman W, Gause B, et al.
N Engl J Med
. 1993 Mar;
328(11):756-61.
PMID: 8437596
Background: Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1 alpha could ameliorate carboplatin-induced thrombocytopenia, we combined it...
10.
Janik J, Kopp W, Smith 2nd J, Longo D, Alvord W, Sharfman W, et al.
J Clin Oncol
. 1993 Jan;
11(1):125-35.
PMID: 8418223
Purpose: This phase I study was conducted to determine the maximum-tolerated dose (MTD) and the immunologic properties of levamisole in cancer patients when administered alone and in combination with interferon...